2012
Cellular basis for clearance of the protozoan parasite Babesia microti in immunocompromised hosts (43.13)
Vannier E, Silver Z, Wilson C, Su J, Chiam J, Laurie S, Telford S, Gelfand J, Krause P, Wortis H. Cellular basis for clearance of the protozoan parasite Babesia microti in immunocompromised hosts (43.13). The Journal Of Immunology 2012, 188: 43.13-43.13. DOI: 10.4049/jimmunol.188.supp.43.13.Peer-Reviewed Original ResearchCD4-/- miceB cellsT cellsMild flu-like illnessBabesia microtiResolution of parasitemiaAbsence of CD4Flu-like illnessRag1-/- miceRole of complementB-cell lymphomaCourse of infectionPrimary etiologic agentMature B cellsCD4-CD8Specific IgGAnti-CD20Athymic miceCell lymphomaFc receptorsHealthy individualsCD4ParasitemiaEtiologic agentInfectious diseases
2008
Persistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis